© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Lonza Group AG (LZAGY) stock surged +1.08%, trading at $74.07 on OTC, up from the previous close of $73.28. The stock opened at $73.28, fluctuating between $73.28 and $74.35 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 25, 2026 | 73.71 | 74.35 | 73.71 | 74.07 | 18.19K |
| Aug 24, 2026 | 73.20 | 73.43 | 72.94 | 73.28 | 229.63K |
| Aug 21, 2026 | 73.33 | 74.00 | 73.25 | 73.87 | 23.42K |
| Aug 20, 2026 | 72.78 | 73.51 | 72.68 | 72.98 | 28.37K |
| Aug 19, 2026 | 72.18 | 72.87 | 72.18 | 72.87 | 31.95K |
| Aug 18, 2026 | 69.54 | 69.96 | 69.47 | 69.56 | 23.61K |
| Aug 17, 2026 | 69.88 | 70.09 | 69.59 | 69.72 | 70.78K |
| Aug 14, 2026 | 68.94 | 69.33 | 68.60 | 69.10 | 19.95K |
| Aug 13, 2026 | 70.44 | 70.88 | 70.36 | 70.40 | 18.52K |
| Aug 12, 2026 | 69.40 | 69.66 | 69.24 | 69.63 | 20.53K |
| Aug 11, 2026 | 70.91 | 71.55 | 70.68 | 70.79 | 18.82K |
| Aug 10, 2026 | 71.00 | 71.52 | 71.00 | 71.40 | 20.32K |
| Aug 07, 2026 | 71.31 | 71.31 | 70.80 | 70.93 | 16.52K |
| Aug 06, 2026 | 69.93 | 69.93 | 69.53 | 69.57 | 22.72K |
| Aug 05, 2026 | 68.57 | 69.60 | 68.57 | 69.51 | 49.46K |
| Aug 04, 2026 | 69.48 | 69.53 | 68.58 | 69.02 | 43.13K |
| Aug 03, 2026 | 69.62 | 69.62 | 69.00 | 69.31 | 23.76K |
| Jul 31, 2026 | 70.53 | 70.53 | 69.15 | 69.59 | 25.62K |
| Jul 30, 2026 | 71.02 | 71.50 | 70.42 | 71.14 | 28.31K |
| Jul 29, 2026 | 68.95 | 70.63 | 68.89 | 69.88 | 71.82K |
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
| Employees | 16866 |
| Beta | 0.84 |
| Sales or Revenue | $6.57B |
| 5Y Sales Change% | 0.225% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |